Primary Sources

PrintPrint EmailEmail ShareShare CiteCite
Style:MLAAPAChicagoClose

loading...

Supreme Court Decision: Association for Molecular Pathology v. Myriad Genetics

Published June 13, 2013

The Supreme Court ruled on June 13, 2013, that Myriad Genetics could not patent two human genes the company isolated from the bloodstream, because the company "did not create anything," though synthetic forms of the genes, methods for isolating the genes, and applications from the study may be eligible for patent.

The SCOTUS blog post related to this decision explained that mutations of the two isolated genes when found in the blood have shown a high risk of ovarian and breast cancer, and that the ruling allows more medical and scientific researchers and doctors the opportunity to study the risk of these cancers for patients.

More on This Topic